MedTrace Logo

Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects

NCT02642679 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this single center, prospective case series is to evaluate the effective management of split-thickness skin graft donor site wounds using Opticell Ag (Chitosan-based dressing).

Conditions

  • Split-thickness Skin Graft Donor Sites

Interventions

DEVICE

Opticell Ag

Opticell Ag+ applied to STSG donor site

Sponsors & Collaborators

  • Medline Industries

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Indranil Sinha, MD · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-10-31
Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02642679 on ClinicalTrials.gov